Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Cummings

Showing results (11-20 of 243) with videos related to

Pageof 25
Sort By:
The Journal of Neuropsychiatry and Clinical Neurosciences|October 28, 2020
Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's DiseaseJeffrey Cummings
Advances in Experimental Medicine and Biology|February 13, 2019
The Role of Biomarkers in Alzheimer's Disease Drug DevelopmentJeffrey Cummings
Translational Neurodegeneration|October 13, 2017
Disease modification and Neuroprotection in neurodegenerative disordersJeffrey Cummings
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 25, 2018
The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trialsJeffrey Cummings
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
The role of reductive enzymes in cancer cell resistance to mitomycin CJeffrey Cummings
Annals of Neurology|November 11, 2008
Primary progressive aphasia and the growing role of biomarkers in neurological diagnosisJeffrey Cummings
Nature Medicine|August 20, 2021
Why aducanumab is importantJeffrey Cummings
Biological Psychiatry|November 2, 2010
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?Jeffrey Cummings
Alzheimer'S & Dementia (New York, N. Y.)|August 1, 2022
Commentary on: A call for better reporting of trials using surrogate primary endpointsJeffrey Cummings
Annals of the Academy of Medicine, Singapore|August 27, 2011
Alzheimer's disease: clinical trials and the amyloid hypothesisJeffrey Cummings
Pageof 25

Showing results (11-20 of 243) with videos related to

Sort By:
Pageof 25
The Journal of Neuropsychiatry and Clinical Neurosciences|October 28, 2020
Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's DiseaseJeffrey Cummings
Advances in Experimental Medicine and Biology|February 13, 2019
The Role of Biomarkers in Alzheimer's Disease Drug DevelopmentJeffrey Cummings
Translational Neurodegeneration|October 13, 2017
Disease modification and Neuroprotection in neurodegenerative disordersJeffrey Cummings
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 25, 2018
The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trialsJeffrey Cummings
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 11, 2001
The role of reductive enzymes in cancer cell resistance to mitomycin CJeffrey Cummings
Annals of Neurology|November 11, 2008
Primary progressive aphasia and the growing role of biomarkers in neurological diagnosisJeffrey Cummings
Nature Medicine|August 20, 2021
Why aducanumab is importantJeffrey Cummings
Biological Psychiatry|November 2, 2010
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?Jeffrey Cummings
Alzheimer'S & Dementia (New York, N. Y.)|August 1, 2022
Commentary on: A call for better reporting of trials using surrogate primary endpointsJeffrey Cummings
Annals of the Academy of Medicine, Singapore|August 27, 2011
Alzheimer's disease: clinical trials and the amyloid hypothesisJeffrey Cummings
Pageof 25